Publications
Filters: First Letter Of Keyword is D [Clear All Filters]
Estimating individualized treatment rules for ordinal treatments." Biometrics 74, no. 3 (2018): 924-933.
"Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data." Biometrics 74, no. 4 (2018): 1180-1192.
"Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme." Biometrics 69, no. 3 (2013): 714-23.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"K-Sample comparisons using propensity analysis." Biom J 61, no. 3 (2019): 698-713.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"A global logrank test for adaptive treatment strategies based on observational studies." Stat Med 33, no. 5 (2014): 760-71.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme." Biometrics 69, no. 3 (2013): 714-23.
"Estimation of treatment effect for the sequential parallel design." Stat Med 30, no. 30 (2011): 3496-506.
"Augmented outcome-weighted learning for estimating optimal dynamic treatment regimens." Stat Med 37, no. 26 (2018): 3776-3788.
"LIBERTI: A SMART study in plastic surgery." Clin Trials 15, no. 3 (2018): 286-293.
"Characterizing expected benefits of biomarkers in treatment selection." Biostatistics 16, no. 2 (2015): 383-99.
"Analysis of untyped SNPs: maximum likelihood and imputation methods." Genet Epidemiol 34, no. 8 (2010): 803-15.
"Semiparametric regression analysis of interval-censored data with informative dropout." Biometrics 74, no. 4 (2018): 1213-1222.
"A model-based conditional power assessment for decision making in randomized controlled trial studies." Stat Med 36, no. 30 (2017): 4765-4776.
"Meta-analysis of genome-wide association studies: no efficiency gain in using individual participant data." Genet Epidemiol 34, no. 1 (2010): 60-6.
"Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk." Stat Methods Med Res 21, no. 6 (2012): 621-33.
"Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program." Stat Med 33, no. 9 (2014): 1600-18.
"Estimating individualized treatment rules for ordinal treatments." Biometrics 74, no. 3 (2018): 924-933.
"A practical Bayesian adaptive design incorporating data from historical controls." Stat Med 37, no. 27 (2018): 4054-4070.
"Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk." Stat Methods Med Res 21, no. 6 (2012): 621-33.
"Estimating personalized diagnostic rules depending on individualized characteristics." Stat Med 36, no. 7 (2017): 1099-1117.
"Block-diagonal discriminant analysis and its bias-corrected rules." Stat Appl Genet Mol Biol 12, no. 3 (2013): 347-59.
"Assessing the dependence of sensitivity and specificity on prevalence in meta-analysis." Biostatistics 12, no. 4 (2011): 710-22.
"Time-dependent classification accuracy curve under marker-dependent sampling." Biom J 58, no. 4 (2016): 974-92.
" "
Performance of rapid influenza H1N1 diagnostic tests: a meta-analysis." Influenza Other Respir Viruses 6, no. 2 (2012): 80-6.
"Multicategory reclassification statistics for assessing improvements in diagnostic accuracy." Biostatistics 14, no. 2 (2013): 382-94.
"Statistical methods for multivariate meta-analysis of diagnostic tests: An overview and tutorial." Stat Methods Med Res 25, no. 4 (2016): 1596-619.
"A hybrid Bayesian hierarchical model combining cohort and case-control studies for meta-analysis of diagnostic tests: Accounting for partial verification bias." Stat Methods Med Res 25, no. 6 (2016): 3015-3037.
"A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard." Biometrics 71, no. 2 (2015): 538-47.
"A composite likelihood method for bivariate meta-analysis in diagnostic systematic reviews." Stat Methods Med Res 26, no. 2 (2017): 914-930.
"Comparison of operational characteristics for binary tests with clustered data." Stat Med 34, no. 15 (2015): 2325-33.
"A simple and robust method for multivariate meta-analysis of diagnostic test accuracy." Stat Med 36, no. 1 (2017): 105-121.
" "
More insights into early brain development through statistical analyses of eigen-structural elements of diffusion tensor imaging using multivariate adaptive regression splines." Brain Struct Funct 219, no. 2 (2014): 551-69.
"Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer." Cancer 121, no. 6 (2015): 836-43.
"Multivariate varying coefficient models for DTI tract statistics." Med Image Comput Comput Assist Interv 13, no. Pt 1 (2010): 690-7.
"Longitudinal regression analysis of spatial-temporal growth patterns of geometrical diffusion measures in early postnatal brain development with diffusion tensor imaging." Neuroimage 58, no. 4 (2011): 993-1005.
"More insights into early brain development through statistical analyses of eigen-structural elements of diffusion tensor imaging using multivariate adaptive regression splines." Brain Struct Funct 219, no. 2 (2014): 551-69.
"Semiparametric Bayesian local functional models for diffusion tensor tract statistics." Neuroimage 63, no. 1 (2012): 460-74.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"FMEM: functional mixed effects modeling for the analysis of longitudinal white matter Tract data." Neuroimage 84 (2014): 753-64.
"A longitudinal functional analysis framework for analysis of white matter tract statistics." Inf Process Med Imaging 23 (2013): 220-31.
"FADTTS: functional analysis of diffusion tensor tract statistics." Neuroimage 56, no. 3 (2011): 1412-25.
"Incorporating covariates in skewed functional data models." Biostatistics 16, no. 3 (2015): 413-26.
"Estimating personalized diagnostic rules depending on individualized characteristics." Stat Med 36, no. 7 (2017): 1099-1117.
"Confident difference criterion: a new Bayesian differentially expressed gene selection algorithm with applications." BMC Bioinformatics 16 (2015): 245.
"Block-diagonal discriminant analysis and its bias-corrected rules." Stat Appl Genet Mol Biol 12, no. 3 (2013): 347-59.
"Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis." Hum Genomics 5, no. 1 (2010): 5-16.
"A general framework for studying genetic effects and gene-environment interactions with missing data." Biostatistics 11, no. 4 (2010): 583-98.
"Improving the efficiency of estimation in the additive hazards model for stratified case-cohort design with multiple diseases." Stat Med 35, no. 2 (2016): 282-93.
"Biclustering via sparse clustering." Biometrics 76, no. 1 (2020): 348-358.
"Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching." Lifetime Data Anal 20, no. 1 (2014): 76-105.
"Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI." Neuroimage 56, no. 3 (2011): 890-906.
"Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
"Multiple kernel learning with random effects for predicting longitudinal outcomes and data integration." Biometrics 71, no. 4 (2015): 918-28.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression." Biometrics 73, no. 4 (2017): 1343-1354.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial." J Clin Oncol 37, no. 8 (2019): 624-635.
"Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia." Ann Oncol 30, no. 4 (2019): 542-550.
"Additive mixed effect model for clustered failure time data." Biometrics 67, no. 4 (2011): 1340-51.
"Bayesian influence measures for joint models for longitudinal and survival data." Biometrics 68, no. 3 (2012): 954-64.
"Empirical pathway analysis, without permutation." Biostatistics 14, no. 3 (2013): 573-85.
"Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690." BMC Med Res Methodol 12 (2012): 183.
"Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test." Stat Med 33, no. 12 (2014): 2004-16.
"Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Bayesian design of a survival trial with a cured fraction using historical data." Stat Med 37, no. 26 (2018): 3814-3831.
"Biclustering with heterogeneous variance." Proc Natl Acad Sci U S A 110, no. 30 (2013): 12253-8.
"Static and Dynamic DNA Loops form AP-1-Bound Activation Hubs during Macrophage Development." Mol Cell 67, no. 6 (2017): 1037-1048.e6.
"Improved detection of epigenomic marks with mixed-effects hidden Markov models." Biometrics 75, no. 4 (2019): 1401-1413.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors." Bioinformatics 27, no. 5 (2011): 678-85.
"Integrative gene set analysis of multi-platform data with sample heterogeneity." Bioinformatics 30, no. 11 (2014): 1501-7.
"A New Method for Detecting Associations with Rare Copy-Number Variants." PLoS Genet 11, no. 10 (2015): e1005403.
"Global copy number profiling of cancer genomes." Bioinformatics 32, no. 6 (2016): 926-8.
"SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling." Genome Biol 18, no. 1 (2017): 66.
"The association between copy number aberration, DNA methylation and gene expression in tumor samples." Nucleic Acids Res 46, no. 6 (2018): 3009-3018.
"Integrative pipeline for profiling DNA copy number and inferring tumor phylogeny." Bioinformatics 34, no. 12 (2018): 2126-2128.
"Allele-specific copy-number discovery from whole-genome and whole-exome sequencing." Nucleic Acids Res 43, no. 14 (2015): e90.
"CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing." Genome Biol 19, no. 1 (2018): 202.
"SCOPE: A Normalization and Copy-Number Estimation Method for Single-Cell DNA Sequencing." Cell Syst 10, no. 5 (2020): 445-452.e6.
"Association test using Copy Number Profile Curves (CONCUR) enhances power in rare copy number variant analysis." PLoS Comput Biol 16, no. 5 (2020): e1007797.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Integrative gene set analysis of multi-platform data with sample heterogeneity." Bioinformatics 30, no. 11 (2014): 1501-7.
"Across-Platform Imputation of DNA Methylation Levels Incorporating Nonlocal Information Using Penalized Functional Regression." Genet Epidemiol 40, no. 4 (2016): 333-40.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Mapping eQTL by leveraging multiple tissues and DNA methylation." BMC Bioinformatics 18, no. 1 (2017): 455.
"The association between copy number aberration, DNA methylation and gene expression in tumor samples." Nucleic Acids Res 46, no. 6 (2018): 3009-3018.
"Intergenerational response to the endocrine disruptor vinclozolin is influenced by maternal genotype and crossing scheme." Reprod Toxicol 78 (2018): 9-19.
"Integrative analysis of sequencing and array genotype data for discovering disease associations with rare mutations." Proc Natl Acad Sci U S A 112, no. 4 (2015): 1019-24.
"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175.
"Single-nucleotide resolution analysis of nucleotide excision repair of ribosomal DNA in humans and mice." J Biol Chem 294, no. 1 (2019): 210-217.
"